Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleNeurology

123I-Iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies

Joachim Mazère, Frédéric Lamare, Michele Allard, Philippe Fernandez and Willy Mayo
Journal of Nuclear Medicine January 2017, 58 (1) 123-128; DOI: https://doi.org/10.2967/jnumed.116.176180
Joachim Mazère
1Université de Bordeaux, INCIA, UMR 5287, Bordeaux, France
2CNRS, INCIA, UMR 5287, Bordeaux, France
3Service de Médecine Nucléaire, CHU de Bordeaux, Bordeaux, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frédéric Lamare
1Université de Bordeaux, INCIA, UMR 5287, Bordeaux, France
2CNRS, INCIA, UMR 5287, Bordeaux, France
3Service de Médecine Nucléaire, CHU de Bordeaux, Bordeaux, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michele Allard
1Université de Bordeaux, INCIA, UMR 5287, Bordeaux, France
2CNRS, INCIA, UMR 5287, Bordeaux, France
3Service de Médecine Nucléaire, CHU de Bordeaux, Bordeaux, France; and
4EPHE, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Fernandez
1Université de Bordeaux, INCIA, UMR 5287, Bordeaux, France
2CNRS, INCIA, UMR 5287, Bordeaux, France
3Service de Médecine Nucléaire, CHU de Bordeaux, Bordeaux, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willy Mayo
1Université de Bordeaux, INCIA, UMR 5287, Bordeaux, France
2CNRS, INCIA, UMR 5287, Bordeaux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Cholinergic alterations in dementia with Lewy bodies (DLB) have been widely documented in postmortem studies, whereas in vivo studies are sparse, particularly at the subcortical level. We used 123I-iodobenzovesamicol, a SPECT radiotracer of the vesicular acetylcholine transporter, to evaluate in vivo in DLB the integrity of the 3 main cholinergic pathways—the Ch1 (septohippocampal), the Ch4 (innominatocortical), and the Ch5 (pontothalamic) cholinergic pathways—as well as the striatal cholinergic interneurons. In addition, we assessed the involvement of the cholinergic system in cognitive and neuropsychiatric disorders in DLB patients. Methods: Twelve healthy volunteers (median age, 72 y; interquartile range, 6.25 y) and 11 DLB patients (median age, 76 y; interquartile range, 10.50 y) underwent a dynamic 123I-iodobenzovesamicol SPECT scan and an MRI scan. MR images were automatically segmented, providing the volumes of several regions of interest, including the striatum and cholinergic terminals in Ch1 (hippocampus), Ch4 (cortical lobes), and Ch5 (thalamus). For each region of interest and each subject, pharmacokinetic modeling allowed calculation of the nondisplaceable binding potential (BPND) values for the binding of 123I-iodobenzovesamicol to the vesicular acetylcholine transporter. A neuropsychological evaluation of participants was performed with the Mini-Mental State Examination and the Grober–Buschke, Set, visual discrimination, Benton, and Wechsler tests, and cognitive fluctuations and apathy were also assessed. Results: Compared with BPND values for healthy subjects, BPND values for DLB patients were significantly lower in the Ch4 terminal regions of the anterior cingulate cortex and the superior and inferior parietal cortices (P = 0.0006, 0.0015, and 0.0023, respectively), in the Ch5 terminal region of the thalamus (P = 0.0003), and in the striatum (P = 0.0042). All of the neuropsychological test scores were significantly lower in DLB patients than in healthy subjects. Four DLB patients with apathy and 4 DLB patients without apathy were identified. For the anterior cingulate cortex, compared with BPND values in healthy subjects, BPND values were significantly lower in patients with apathy (P = 0.004) and were unchanged in patients without apathy. Conclusion: Our results confirm the existence in DLB of cholinergic alterations, reaching both cortical and subcortical levels, including the Ch5 pathway and the striatum. Alterations in cholinergic transmission in the anterior cingulate cortex could be closely associated with the development of apathy.

  • 123I-iodobenzovesamicol
  • SPECT
  • cholinergic pathways
  • dementia with Lewy Bodies
  • apathy

Footnotes

  • Published online Jul. 28, 2016.

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (1)
Journal of Nuclear Medicine
Vol. 58, Issue 1
January 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
123I-Iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
123I-Iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies
Joachim Mazère, Frédéric Lamare, Michele Allard, Philippe Fernandez, Willy Mayo
Journal of Nuclear Medicine Jan 2017, 58 (1) 123-128; DOI: 10.2967/jnumed.116.176180

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
123I-Iodobenzovesamicol SPECT Imaging of Cholinergic Systems in Dementia with Lewy Bodies
Joachim Mazère, Frédéric Lamare, Michele Allard, Philippe Fernandez, Willy Mayo
Journal of Nuclear Medicine Jan 2017, 58 (1) 123-128; DOI: 10.2967/jnumed.116.176180
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders
  • Google Scholar

More in this TOC Section

Neurology

  • Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
Show more Neurology

Clinical Investigation

  • [18F]FDG PET/CT Predicts Patient Survival in Patients with Systemic Sclerosis–Associated Interstitial Lung Disease
  • Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View
  • Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
Show more Clinical Investigation

Similar Articles

Keywords

  • 123I-iodobenzovesamicol
  • SPECT
  • cholinergic pathways
  • dementia with Lewy Bodies
  • apathy
SNMMI

© 2025 SNMMI

Powered by HighWire